Study Summary
This trial is testing a new pain reliever for people with chronic neuropathic pain. The study is done remotely, with four visits over teleconferencing, and the study devices mailed to participants to use at home for 8-14 weeks.
- Neuropathic Pain
- Chronic Pain
- Pain
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
Trial Safety
Phase-Based Safety
Trial Design
2 Treatment Groups
"Real" SPR
1 of 2
Sham SPR
1 of 2
Experimental Treatment
Non-Treatment Group
102 Total Participants · 2 Treatment Groups
Primary Treatment: Sana Pain Reliever · Has Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| New York | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Icahn School of Medicine at Mount Sinai | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Frequently Asked Questions
Could you provide information on the current enrollment status of this clinical experiment?
"Indeed, the data hosted on clinicaltrials.gov suggests that this experiment is presently enrolling participants. Originally posted in January of 2020 and recently updated April 22nd 2022 , the medical trial seeks 100 individuals at 1 site." - Anonymous Online Contributor
Could you provide an estimate of the size of the cohort engaged in this research?
"Affirmative. Clinicaltrials.gov displays that this experiment is actively recruiting, having first been posted on January 16th 2020 and most recently modified on April 22nd 2022. A total of 100 patients are needed for the trial to be conducted at a single medical site." - Anonymous Online Contributor